Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 312 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypothalamic-pituitary Disorders Clear all

Conditions: Growth Hormone Deficiency
Interventions: LUM-201, rhGH Norditropin® pen (34 µg/kg); Drug
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 27
States / cities: Sacramento, California • San Diego, California • Greenwood Village, Colorado + 24 more

Conditions: Acromegaly
Interventions: ONO-5788, ONO-5788 Placebo, Octreotide; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions: somapacitan, somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 23 Years to 79 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more

Conditions: Acromegaly
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Growth Hormone Deficiency
Interventions: Somatropin; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 3 Years to 14 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 33
States / cities: Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more

Conditions: Inappropriate ADH Syndrome, Hyponatremia
Interventions: SR121463B; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Pituitary Neoplasm
Interventions: Acthrel; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 8 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
Interventions: atumelnant; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sellar and Suprasellar Masses, Pituitary Tumor
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cushing's Syndrome
Interventions: mifepristone; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 17
States / cities: Birmingham, Alabama • Escondido, California • Stanford, California + 13 more

Conditions: Growth Hormone Deficiency
Interventions: growth hormone (Nutropin); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 17 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypopituitarism
Interventions: TheraDerm; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease, Peutz-Jeghers Syndrome
Interventions: oCRH; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 70 Years
Enrollment: 1,387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pituitary Neoplasm, Pituitary Adenoma, Prolactinoma, Cushings Disease, Acromegaly
Interventions: Not listed
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 80 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Phoenix, Arizona • Santa Monica, California • Chicago, Illinois + 1 more

Conditions: Childhood-onset Growth Hormone Deficiency, Pituitary Dwarfism
Interventions: recombinant human growth hormone; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 13 Years to 25 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Orange, California • Jacksonville, Florida • Orlando, Florida + 6 more

Conditions: Dwarfism, Pituitary
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: South San Francisco, California

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
Interventions: Not listed
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Menopause
Interventions: TA, AA, WC; Procedure · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypopituitarism, Hypogonadism, Growth Hormone Deficiency
Interventions: Testosterone plus somatropin, testosterone; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adult Growth Hormone Deficiency
Interventions: ALTU-238; Drug
Lead sponsor: Altus Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Louisville, Kentucky • Galveston, Texas • San Antonio, Texas

Conditions: Cushings Disease
Interventions: Pasireotide; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more

Conditions: Brain Injuries, Growth Hormone Deficiency Dwarfism
Interventions: somatropin; Genetic
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 4
States / cities: Pittsburgh, Pennsylvania • El Paso, Texas • Salt Lake City, Utah + 1 more

Conditions: Infertility, Female, Obesity
Interventions: Estradiol Patches; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Brain Tumor, Recurrent
Interventions: Photofrin (porfimer sodium) & photodynamic therapy.; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 6 Months to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Search by objective public record fields.

Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Effects of Hormone Stimulation on Brain Scans for Cushing s Disease

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

304-C03/L3301n: Effects of Growth Hormone on Glucose and Protein Metabolism in Children With Growth Hormone Deficiency

Androgen Replacement Therapy in Women With Hypopituitarism

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Rhinological Outcomes in Endonasal Pituitary Surgery

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

Pilot Study - Impact of Traditional Acupuncture on Menopause

Testosterone and Growth Hormone for Bone Loss in Men

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

A Study to Evaluate the Efficacy of Somatropin in Adults With Growth Hormone Deficiency Caused by Trauma and/or Head Injury

Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors